Biotechnology

A Boston biotech says its new AI platform moves beyond correlation to find the true biological causes of disease, promising a new era for medicine.

A novel immunotherapy tames a potent but toxic cancer-fighting agent by locking it inside tumors, offering new hope for patients with resistant cancers.

Quintara Biosciences launches AmpValue, a $4.99 overnight sequencing service set to disrupt biotech by making advanced, full-length data accessible to all.

A new oral therapy shows a 76% response rate in a hard-to-treat lung cancer, offering a powerful new first-line option for patients with this rare disease.

Biopharma leader Dr. Gavin Barnard joins ATUM as CSO, aiming to leverage AI and advanced tech to fast-track complex therapies from the lab to the clinic.

With founder Frédéric Mascha as Executive Chairman and new CEO Renaud Sermondade, Juvisé Pharmaceuticals is poised for major M&A-fueled global expansion.

Inventia Life Science's new RASTRUM Validated Solutions offer standardized 3D models to tackle the reproducibility crisis in pharmaceutical R&D.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

Despite major cost cuts and growth in key divisions, DSS, Inc. struggles to convince Wall Street. Can a biotech spin-off finally unlock its true value?

With key advisory appointments, NeuraClick aims to overcome long-standing hurdles in peptide drug development for complex brain and metabolic disorders.

A new biotech player is advancing a first-in-class cancer drug that combines two payloads to fight tumors that have become resistant to current therapies.

A CEO's personal battle with prostate cancer inspired a community golf tournament that is now on the verge of raising $1 million for critical research.

Backed by Bain Capital and a veteran team, the new biotech has a de-risked pipeline from Bristol Myers Squibb aimed at transforming care for lupus and more.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

At a major oncology conference, Zephyr AI will showcase AI that predicts patient response to targeted therapies, aiming to personalize cancer treatment.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

Following a major partnership, AST and Marchesini Group will showcase next-gen robotic filling and inspection tech, aiming to reshape sterile drug production.

With new top-tier executives, Danish biotech MinervaX is accelerating its quest to deliver the world's first vaccine against a leading cause of infant death.